Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently under clinical development for obesity and type 2 diabetes
PubReader Cite Cite Close Download Citation Close XML Download Figure Fig
In February 2021, the researchers published the findings from their trial in The New England Journal of Medicine, showing that patients using semaglutide lost almost 15% of their body weight, on average, compared with 2.4% among patients who got the placebo
It's important for anyone with these symptoms to see a doctor quickly
US$ 22.92
US$ 29.96
US$ 22.12
US$ 27.17
US$ 28.46
